Pancreatic cancer remains to be one of the most challenging malignancies in modern oncology. Despite great progress in surgery, chemotherapy and radiation therapy, the prognosis for pancreatic cancer is still extremely poor with a five-year mortality rate of almost 100%. To date, the exact mechanisms of the onset and progression of pancreatic cancer have not yet been elucidated, and there are no molecular markers that would allow the development of effective therapy.
Today, targeted analysis of a wide range of numerous genes associated with cancer development has become possible. The identification of specific molecular markers for various pancreatic neoplasms, in particular micro-RNA (mi-RNA), will significantly increase the effectiveness of therapy. Mi-RNAs are a group of small, non-coding RNA molecules and can presumably be used to determine the malignancy of pancreatic adenocarcinoma, metastasis to regional lymph nodes and clinical prognosis.
For more read the news of the WCRC for Personalized Medicine.